Monday 21 October 2019 ,
Monday 21 October 2019 ,
Latest News
  • Drive against militancy, drugs, casinos to continue: Home minister
  • 4 killed in Bhola clash over Facebook post
  • PM calls for boosting trade, commerce with Vietnam
  • DU ‘ Ka’, ‘Cha’ units results published: Pass rate of 13.05 and 2.50 percent respectively.
  • Quader attributes Menon's election comment to 'personal
  • JCD men come under attack at DU; 4 injured
24 June, 2019 00:00 00 AM

FDA approves Zolgensma (onasemnogene abeparvovec-xioi) gene therapy to treat Spinal Muscular Atrophy

drugs.com
FDA approves Zolgensma (onasemnogene abeparvovec-xioi) gene therapy to treat Spinal Muscular Atrophy

The U.S. Food and Drug Administration recently approved Zolgensma (onasemnogene abeparvovec-xioi), the first gene therapy approved to treat children less than two years of age with spinal muscular atrophy (SMA), the most severe form of SMA and a leading genetic cause of infant mortality.

“The approval marks another milestone in the transformational power of gene and cell therapies to treat a wide range of diseases,” said Acting FDA Commissioner Ned Sharpless, M.D. “With each new approval, we see this exciting area of science continue to move beyond the concept phase into reality. The potential for gene therapy products to change the lives of those patients who may have faced a terminal condition, or worse, death, provides hope for the future. The FDA will continue to support the progress in this field by helping to expedite the development of products for unmet medical needs through the use of review pathways designed to advance innovative, safe and effective treatment options.”

SMA is a rare genetic disease caused by a mutation in the survival motor neuron 1 (SMN1) gene. The gene encodes the survival motor neuron (SMN) protein – a protein found throughout the body, which is critical for the maintenance and function of specialized nerve cells, called motor neurons. Motor neurons in the brain and spinal cord control muscle movement throughout the body. If there is not enough functional SMN protein, then the motor neurons die, leading to debilitating and often fatal muscle weakness.

SMA caused by mutations in the SMN1 gene is generally classified into several subtypes, based on the age of onset and severity; infantile-onset SMA is the most severe and most common subtype. Children with this condition have problems holding their head up, swallowing and breathing. These symptoms may be present at birth or may present by the age of 6 months.

“Children with SMA experience difficulty performing essential functions of life. Most children with this disease do not survive past early childhood due to respiratory failure” said Peter Marks, M.D., Ph.D., director of the FDA’s Center for Biologics Evaluation and Research. “Patients with SMA now have another treatment option to minimize the progression of SMA and improve survival. This approval demonstrates the continued momentum of this promising new area of medicine and the FDA’s commitment to supporting and helping expedite the development of these products.”

Zolgensma is indicated for the treatment of children less than two years of age with SMA. The product is an adeno-associated virus vector-based gene therapy that targets the cause of SMA. The vector delivers a fully functional copy of human SMN gene into the target motor neuron cells.

A one-time intravenous administration of Zolgensma results in expression of the SMN protein in a child’s motor neurons, which improves muscle movement and function, and survival of a child with SMA. Dosing is determined based on the weight of the patient.

The safety and effectiveness of Zolgensma is based on an ongoing clinical trial and a completed clinical trial involving a total of 36 pediatric patients with infantile-onset SMA between the ages of approximately 2 weeks and 8 months at study entry.

In this trial, there are 19 remaining patients, who range in age from 9.4 to 18.5 months; 13 of these 19 patients are at least 14 months of age. Compared to the natural history of patients with infantile-onset SMA, patients treated with Zolgensma also demonstrated significant improvement in their ability to reach developmental motor milestones (e.g., head control and the ability to sit without support).

The most common side effects of Zolgensma are elevated liver enzymes and vomiting. Zolgensma has a boxed warning that acute serious liver injury can occur. Patients with pre existing liver impairment may be at higher risk of experiencing serious liver injury.

Clinical examination and laboratory tests to assess liver function should be completed prior to treatment with Zolgensma, and patients’ liver function should be monitored for at least three months after Zolgensma administration.

Certain vaccines are contraindicated for patients on a substantially immunosuppressive steroid dose. Therefore, caregivers should consult with their healthcare professional to determine if adjustments to the patient’s vaccination schedule are necessary to accommodate concomitant corticosteroid administration.

Comments

Most Viewed
Digital Edition
More story
Editor Speaks

Editor Speaks

Osteoporosis is commonest metabolic bone disease, occurs in old age and different from osteomalacia - rickets. There is progressive decrease in the density…
Osteoporosis

Osteoporosis

Osteoporosis is a condition characterized by a decrease in the density of bone, decreasing its strength and resulting in fragile bones. Osteoporosis literally…
WHO criteria for diagnosis of osteoporosis

WHO criteria for diagnosis of osteoporosis

Under the auspices of the World Health Organization (WHO), a panel of experts has periodically met on the topic of assessment of fracture risk and osteoporosis.…
Osteoporosis: An epidemic with dire consequences

Osteoporosis: An epidemic with dire consequences

Osteoporosis, which literally means porous bone, is reduced bone mass per unit volume thus predisposing the person with it to an increased risk of fracture.…
An overview of juvenile osteoporosis

An overview of juvenile osteoporosis

LANA BARHUM Osteoporosis a progressive bone disease where bone density is lost or there is insufficient bone formation. The result is weakened bones and…
How to cope with some of the most difficult menopause symptoms

How to cope with some of the most difficult menopause symptoms

 ALICE OGLETHORPE Menopause happens to every single woman, but that doesn’t mean the symptoms—or best treatments—are the same for…
Melanoma stages: Prognosis, survival rates and treatment

Melanoma stages: Prognosis, survival rates and treatment

LISA ESPOSITO Melanoma is one of the most serious forms of skin cancer. In early stages, it may be treated through relatively simple surgery, but advanced…
When to be concerned about constant ringing in your ears

When to be concerned about constant ringing in your ears

 BETH KRIETSCH Have you ever experienced ringing, buzzing, hissing or other noises that no one else around you seems to hear — and you wonder…
The health benefits of cinnamon essential oil

The health benefits of cinnamon essential oil

CATHY WONG Cinnamon essential oil is a type of essential oil used in aromatherapy. The oil has a warm, sweet aroma, and is sourced from the bark of the…
5th International Medical Mission 2019 held in Dhaka

5th International Medical Mission 2019 held in Dhaka

Week-long 5th International Medical Mission held in Dhaka from 12-17 October 2019 organized by Rotary Club of Dhaka Mavericks with the collaboration of…
Microphone could diagnose 'noisy' arthritic knees

Microphone could diagnose 'noisy' arthritic knees

Technology used by engineers to listen for faults in bridges could be used to diagnose 'noisy' arthritic knees, a study suggests. It involved…
1st Scientific Congress on Non-communicable Diseases held in Dhaka

1st Scientific Congress on Non-communicable Diseases held in Dhaka

The Clinical Research Platform, Bangladesh, a tripartite initiative of icddr,b, Bangabandhu Sheikh Mujib Medical University (BSMMU) and the British Medical…
Lilly's REYVOW™ (lasmiditan), the first and only medicine in a new class of acute treatment for migraine, receives FDA approval

Lilly's REYVOW™ (lasmiditan), the first and only medicine in a new class of acute treatment for migraine, receives FDA approval

Eli Lilly and Company (LLY) announced recently that the U.S. Food and Drug Administration (FDA) has approved REYVOW™ (lasmiditan) an oral medication…

Copyright © All right reserved.

Editor : M. Shamsur Rahman

Published by the Editor on behalf of Independent Publications Limited at Media Printers, 446/H, Tejgaon I/A, Dhaka-1215.
Editorial, News & Commercial Offices : Beximco Media Complex, 149-150 Tejgaon I/A, Dhaka-1208, Bangladesh. GPO Box No. 934, Dhaka-1000.

Editor : M. Shamsur Rahman
Published by the Editor on behalf of Independent Publications Limited at Media Printers, 446/H, Tejgaon I/A, Dhaka-1215.
Editorial, News & Commercial Offices : Beximco Media Complex, 149-150 Tejgaon I/A, Dhaka-1208, Bangladesh. GPO Box No. 934, Dhaka-1000.

Disclaimer & Privacy Policy
....................................................
About Us
....................................................
Contact Us
....................................................
Advertisement
....................................................
Subscription

Powered by : Frog Hosting